---
title: "editorial yes metformin diauetes"
year: 2024
month: 03
journal: "American Family Physician"
volume: "109-110"
issue: "03"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-03-editorial-yes-metformin-diabetes.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial yes metformin diauetes

                                                                 Editorials
                                                 Controversies in Family Medicine

                        Should Metformin Continue
                       as First-Line Pharmacotherapy
                     for Patients With Type 2 Diabetes?
Yes:​Metformin Is Still the Best Choice                                             guidelines, including those from the International Diabetes
Gregory Castelli, PharmD, FCCP, BCPS,                                               Federation, American Association of Clinical Endocrinol-
BC-ADM, CDCES, and Stacy J. Bartlett, MD                                            ogy, and American College of Physicians.7-9
University of Pittsburgh, Pittsburgh, Pennsylvania                                     A recent network meta-analysis joined a growing body of
                                                                                    literature questioning the best initial strategy for managing
Metformin has been the first-line treatment for type 2 diabe-                       type 2 diabetes.10 Some contend that metformin should be
tes mellitus for decades. The glucose-lowering effects of met-                      de-emphasized in favor of newer treatments. However, a
formin were first discovered in the 1920s.1 After extensive                         closer look at the trials leading to this conclusion is needed.
use throughout Europe, the U.S. Food and Drug Adminis-                              Notably, the FDA published guidance in 2008 requiring
tration (FDA) approved metformin for the treatment of type                          drug companies to evaluate the arteriosclerotic cardiovas-
2 diabetes with a 1995 randomized controlled trial demon-                           cular disease (ASCVD) benefits and harms of new diabetes
strating metformin’s safety and efficacy.2 Following two                            therapies.11 Metformin, having long been approved for dia-
decades of widespread use in the United States, extended-                           betes management, was not subject to this requirement.
release and combination formulations were introduced.                                  During the years the FDA guidance was in effect (2008
  Adding to the known glycemic effects of metformin, the                            to 2020), two novel classes of medications were developed,
10-year United Kingdom Prospective Diabetes Study found                             studied, and marketed:​sodium-glucose cotransporter-2
improvement in patient-oriented outcomes, specifically                              (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)
diabetes-related endpoints, stroke, and mortality.3 Of note,                        receptor agonists. Both have been shown to reduce ASCVD
85% of participants randomized to protocols including met-                          events in patients with type 2 diabetes, leading to questions
formin had their dosage titrated up to a maximum of 2,550                           about whether they should be considered first-line ther-
mg per day. A follow-up randomized controlled study in                              apy.12-16 However, these trials focused on patients with a
2008 showed a long-term benefit with early initiation of met-                       history of ASCVD or at high risk for a first ASCVD event,
formin, with risk reductions in diabetes-related endpoints,                         which may not apply to all patients with diabetes who pres-
diabetes-related death, myocardial infarction, and death                            ent in primary care settings.
from any cause.4 This study shifted primarily sulfonylurea-                            For example, the LEADER trial evaluated the ASCVD
based regimens to metformin-first regimens for the treat-                           effects of liraglutide.15 In this trial, patients had established
ment of non–insulin-dependent diabetes. Subsequent                                  ASCVD and were 50 years or older with at least one coex-
studies demonstrating reduced mortality in populations                              isting cardiovascular condition or 60 years or older with at
with atherothrombosis or heart failure and its affordable                           least one cardiovascular risk factor. Although liraglutide
cost further solidified metformin as the preferred initial                          showed benefit in patients with established ASCVD (hazard
treatment for diabetes.5,6 Metformin is the most commonly                           ratio [HR] = 0.83;​95% CI, 0.74 to 0.93), there was no benefit
prescribed glucose-lowering medication worldwide and the                            for those without ASCVD (HR = 1.20;​95% CI, 0.86 to 1.67).
recommended initial pharmacologic option in major clinical                          Empagliflozin (Jardiance) was studied in the EMPA-REG
                                                                                    trial, in which all participants had established ASCVD.12
                                                                                    Although treatment showed benefit for the primary com-
   This is one in a series of pro/con editorials discussing con-
   troversial issues in family medicine.                                            posite outcome (10.5% vs. 12.1%;​HR = 0.86;​95% CI, 0.74 to
   See related editorial on page 202.
                                                                                    0.99), the only individual outcome of the composite to show
                                                                                    a benefit was cardiovascular death, which was determined by
   A collection of Editorials:​Controversies in Family Medicine
   published in AFP is available at https://​www.aafp.org/afp/                      presumed cardiovascular death and worsening heart failure.
   pro-con.                                                                         Because many meta-analyses are based on composite out-
   Author disclosure:​No relevant financial relationships.                          comes of included trials instead of individual-level patient
                                                                                    data, nuances like these do not make the headlines.

200  American
Downloaded        Family
            from the      Physician
                     American   Family Physician website at www.aafp.org/afp.           © 2024 American Academy Volume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                     of Family 109,
                                                                                                                                  Physicians.
                                                                                                                                       Number For 3the private,
                                                                                                                                                    ◆  March non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                                                                2024
                                                                    EDITORIALS


   A 2022 consensus report from the American Diabe-                             5. Roussel R, Travert F, Pasquet B, et al.;​Reduction of Atherothrombosis
                                                                                   for Continued Health Registry Investigators. Metformin use and mor-
tes Association and European Association for the Study                             tality among patients with diabetes and atherothrombosis. Arch Intern
of Diabetes removed metformin as first-line therapy and                            Med. 2010;​170(21):​1892-1899.
focused on goal-based therapy, such as secondary ASCVD                          6. Clarke P, Gray A, Adler A, et al.;​United Kingdom Prospective Diabetes
reduction in patients with established ASCVD, prevent-                             Study. Cost-effectiveness analysis of intensive blood-glucose control
                                                                                   with metformin in overweight patients with type II diabetes. Diabetolo-
ing the progression of chronic kidney disease, and weight                          gia. 2001;​4 4(3):​298-304.
management.17 However, selecting therapy to meet patient                        7. International Diabetes Federation. IDF clinical practice recommendations
goals is the approach every clinician should use for those                         for managing type 2 diabetes in primary care. 2017. Accessed October 22,
                                                                                   2023. https://​idf.org/media/uploads/2023/05/attachments-63.pdf
with type 2 diabetes;​this does not automatically exclude                       8. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical
the use of metformin. The goals for each patient are differ-                       Endocrinology consensus statement:​comprehensive type 2 diabetes
ent and include considerations such as costs, adverse effects,                     management algorithm - 2023 update [published corrections appear
                                                                                   in Endocr Pract. 2023;​29(9):​746 and Endocr Pract. 2023;​29(12):​1025].
and administration. Metformin’s established safety and                             Endocr Pract. 2023;​29(5):​305-340.
effectiveness at A1C reduction—in addition to its relatively                    9. Qaseem A, Barry MJ, Humphrey LL, et al. Oral pharmacologic treat-
low cost and widespread availability to patients—make it                           ment of type 2 diabetes mellitus:​a clinical practice guideline update
                                                                                   from the American College of Physicians. Ann Intern Med. 2017;​166(4):​
an ideal first-line option for many patients with diabetes.
                                                                                   279-290.
Because of safety concerns, metformin is preferred over                        10. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment
other older and inexpensive options such as sulfonylureas                          for type 2 diabetes:​systematic review and network meta-analysis of
and thiazolidinediones.9                                                           randomised controlled trials. BMJ. 2023;​381:​e074068.
                                                                               11. U.S. Food and Drug Administration. Guidance for industry on diabetes
   Metformin should be included in first-line medication                           mellitus-evaluating cardiovascular risk in new antidiabetic therapies to
regimens. Whether additional therapies are started con-                            treat type 2 diabetes; availability. December 18, 2008. Accessed Feb-
currently or deferred depends on individual patient goals.                         ruary 7, 2024. https://www.federalregister.gov/documents/2008/12/19/
                                                                                   E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-
Primary care physicians should not overstate the ASCVD                             cardiovascular-risk-in-new-antidiabetic
benefits of SGLT-2 inhibitors and GLP-1 receptor agonist                       12. Zinman B, Wanner C, Lachin JM, et al.;​EMPA-REG OUTCOME Investi-
medications.                                                                       gators. Empagliflozin, cardiovascular outcomes, and mortality in type 2
                                                                                   diabetes. N Engl J Med. 2015;​373(22):​2117-2128.
Address correspondence to Gregory Castelli, PharmD, FCCP,                      13. Neal B, Perkovic V, Mahaffey KW, et al.;​CANVAS Program Collaborative
BCPS, BC-ADM, CDCES, at castellig@​upmc.edu. Reprints are not                      Group. Canagliflozin and cardiovascular and renal events in type 2 dia-
available from the authors.                                                        betes. N Engl J Med. 2017;​377(7):​6 44-657.
                                                                               14. Wiviott SD, Raz I, Bonaca MP, et al.;​DECLARE–TIMI 58 Investigators.
References                                                                         Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl
                                                                                   J Med. 2019;​380(4):​3 47-357.
 1. Bailey CJ. Metformin:​historical overview. Diabetologia. 2017;​60(9):​
                                                                               15. Marso SP, Daniels GH, Brown-Frandsen K, et al.;​LEADER Steering Com-
    1566-1576.
                                                                                   mittee;​LEADER Trial Investigators. Liraglutide and cardiovascular out-
2. DeFronzo RA, Goodman AM;​The Multicenter Metformin Study Group.                 comes in type 2 diabetes. N Engl J Med. 2016;​375(4):​311-322.
   Efficacy of metformin in patients with non-insulin-dependent diabetes       16. Gerstein HC, Colhoun HM, Dagenais GR, et al.;​REWIND Investigators.
   mellitus. N Engl J Med. 1995;​333(9):​5 41-549.                                 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND):​
3. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose          a double-blind, randomised placebo-controlled trial. Lancet. 2019;​
   control with metformin on complications in overweight patients with             394(10193):​1 21-130.
   type 2 diabetes (UKPDS 34) [published correction appears in Lancet.         17. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia
   1998;​352(9139):​1558]. Lancet. 1998;​352(9131):​854-865.                       in type 2 diabetes, 2022. A consensus report by the American Diabetes
4. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glu-       Association (ADA) and the European Association for the Study of Diabe-
   cose control in type 2 diabetes. N Engl J Med. 2008;​359(15):​1577-1589.        tes (EASD). Diabetes Care. 2022;​45(11):​2753-2786. ■




March 2024 ◆ Volume 109, Number 3                               www.aafp.org/afp                                   American Family Physician 201
